Identifying biomarkers for selection of patients to target tumours harbouring ATM truncating mutations or ATM protein loss, TP53 mutations, BRCA1 or BRCA2 mutations, or other alterations conferring homologous recombination repair deficiency is key for treatment success. This evidence concerns the gene BRCA2 and neoplasm.